EXCLUSIVE: Adial Pharmaceuticals Announces New US Patent Covering Its Molecular Genetic Diagnosing For Alcohol, Drug Dependence
Portfolio Pulse from Vandana Singh
Adial Pharmaceuticals Inc (NASDAQ:ADIL) has been granted a new U.S. patent for its genetic diagnostic approach combined with its investigational drug AD04, aimed at treating alcohol and drug dependencies. This patent enhances the company's intellectual property for diagnosing and potentially treating alcohol use disorder (AUD) and opioid use disorder (OUD) through genetically targeted treatment. The company's CEO, Cary Claiborne, highlighted the significant market potential for AD04, estimated at $40 billion in the U.S., especially among patients with specific genotypes.
February 13, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Adial Pharmaceuticals Inc has received a new U.S. patent for its genetic diagnostic and AD04 drug combination, targeting AUD and OUD, with a potential $40 billion market in the U.S.
The granting of a new U.S. patent to Adial Pharmaceuticals for its genetic diagnostic and AD04 drug combination significantly enhances the company's intellectual property portfolio and market potential. This development could attract investor interest due to the large addressable market and the progress in the company's pipeline, potentially leading to a positive short-term impact on ADIL's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100